Please read the guidelines in full before submitting your manuscript.
Manuscripts not conforming to these guidelines may be returned.
This Journal is a member of the Committee on Publication Ethics.
The Journal recommends that authors follow the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals formulated by the International Committee of Medical Journal Editors (ICMJE).
Sage is committed to upholding the integrity of the academic record. We encourage authors to refer to the Committee on Publication Ethics’ International Standards for Authors and view the author responsibilities section on the Sage Journal Author Gateway.
We also encourage you to familiarize yourself with our Editorial Policies and our Publication Ethics Policies.
Sage Publishing disseminates high-quality research and engaged scholarship globally, and we are committed to diversity and inclusion in publishing. We encourage submissions and peer review from a diverse range of authors and reviewers from across all countries and backgrounds. Read our diversity, equity, and inclusion pledge.
Please read the guidelines below then submit your manuscript here.
Access: Open Access
APC: See article processing charge information below
Accepts preprints? Yes
Identity transparency: Single anonymized
Journal of Parkinson’s Disease is an open access, peer-reviewed journal. All accepted articles are made freely available online immediately upon publication, are published under a Creative Commons license, and hosted online in perpetuity.
If, after peer review, your manuscript is accepted for publication, a one-time article processing charge (APC) is payable to cover the cost of publishing, paid by the funder, institution, or author. There is no charge for submitting a manuscript.
The article processing charge (APC) is $3000.
The article processing charge (APC) is payable when a manuscript is accepted after peer review, before it is published. The APC is subject to taxes where applicable. Tax-exempt status can be indicated by providing appropriate registration numbers when payment is requested. Please see further details on tax-exempt status here.
For general information on open access at Sage please visit the Open Access page.
Authors may be eligible for discounts to their APC via open access agreements that Sage has with participating institutions. Discounts depend on the terms of the agreement, find out if your institution is participating by visiting Open Access Agreements at Sage. Eligibility is determined by the corresponding author’s affiliation at acceptance matching an agreement.
Your article may be eligible for a full or partial waiver due to our participation in initiatives to increase accessibility to publication across the international academic community. More information about discounts and eligibility.
Your article must be within the scope of the journal and be of sufficient quality. If not, it will not be reviewed. Please read the journal’s Aims and Scope to see if your article is appropriate.
The manuscript must be your original work, you must have the rights to the work, and you must have obtained and be able to supply all necessary permissions for the reproduction of any copyright works not owned by you, including figures, illustrations, tables, lengthy quotations, or other material previously published elsewhere.
Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstracts.
Research Reports
Organization and style of presentation
Manuscripts must be written in US English. Authors whose native language is not English are recommended to seek the advice of a native English speaker or English language service before submitting their manuscripts.
Abbreviations: Authors should strive to minimize the use of abbreviations. Policy is to use no more than 5 abbreviations in your manuscript; preference is for authors to write most terms fully. This will improve the readability of papers.
Word count: There are no specific limits, but the Editors-in-Chief ask that all articles are as concise and succinct as possible. As a broad guideline, research articles are usually between 2000-4000 words.
Reviews
Reviews should be authoritative and topical and provide comprehensive and balanced coverage of a timely and/or controversial issue. Reviews should be prepared as detailed above for a Research Report omitting Introduction through Discussion, and include a Conclusion. There is no word count limit, but the Editors-in-Chief ask to keep the manuscript to the point and non-repetitive.
Short Communications
A short communication is an article of original scholarship of unusual interest of less than 1500 words (not including references). An abstract of 100 words or less should be included with no subdivision of text into sections. References should be formatted as above. A total of two tables and/or figures are allowed.
Case reports
The Journal of Parkinson's Disease infrequently publishes clinical descriptions of a single case or a very small case series. These case reports should describe a new or unexpected clinical observation that may have implications for daily clinical care, or that could inspire further research. Submissions for this category should include a brief introduction, a detailed description of the clinical case, followed by a succinct summary of the implications for either daily clinical care or for further research. We welcome the inclusion of videos that illustrate the clinical phenomenon that is being described, if applicable. Case reports should not exceed a maximum of 1500 words.
Global Parkinson’s Disease Articles
This section is edited by Associate Editor Roongroj Bhidayasiri. This section aims to highlight the diverse challenges and unique features of PD in different geographical regions. We welcome original research in clinical medicine, translational research, and basic science from all members of the PD healthcare and research communities for this new section. The goal is to share effective solutions and celebrate successful strategies or efforts being made to overcome the challenges being faced in countries and regions around the world. This may include the pathophysiology of PD, impact of environmental factors, access to and availability of treatments, and use of new technologies to improve care provision. Articles should follow the format of a research article or short communication.
Editorial: Tackling Parkinson’s Disease as a Global Challenge
Replication Studies
Authors who are interested in submitting a replication study should first send a short presubmission enquiry to the editors-in-chief indicating which experiment(s) they are attempting to replicate. Only those authors who receive a positive response to their presubmission enquiry should proceed to submitting their full manuscript. Replication studies should present previously unpublished results from experiments that attempt to replicate previously published high-impact publications within the Parkinson’s disease field. These studies should present data resulting from direct replications or very close conceptual replications of one or more key experiments from other laboratories. They must have been performed by a group or groups independent of those that published the original study. Replication studies should have appropriate controls, sufficient statistical power, and adequate characterization of reagents, biosamples, and laboratory models. Whether the results are negative or positive, the authors should attempt to clarify any points of contention around original findings and/or provide reasonable explanations for deviations from the original findings.
When submitting, select the article type “Replication Study”. The publishing charge for Replication Studies is waived.
"How I Examine My Patient" Articles
The section “How I Examine My Patient" hosts short and clinical summaries of the application and results of standard diagnostic tests and therapies. These articles could concern history taking, physical examination or ancillary tests and the description should be concrete, for use in everyday clinical practice.
Articles should be a maximum of 750 words with a maximum of 8 references in the following format:
One illustrative figure or video, and a summary table may be included.
"Advice to People with Parkinson's in My Clinic" Articles
For this specific section of the journal, we are seeking submissions around clinically relevant questions that commonly arise in daily clinical practice, but for which there is at this point insufficient scientific evidence to make a definitive recommendation. The paper should always have the following structure for the title: "Advice to people with Parkinson's in my clinic: Exercise" or "Advice to people with Parkinson's in my clinic: Cannabis" (exercise and cannabis were just recent examples here).
For the structure of the text itself, we allow fair degree of flexibility, although we recommend that you start by describing why the clinical question that you discuss is actually a commonly occurring problem in clinical practice, and then focus on discussing whatever evidence is available, but also highlighting the lack thereof. Importantly, each paper should end with a dedicated section with the header "What we tell people with Parkinson's in our clinic?"
The typical word count for such a paper would be around 1500 words, although we are open to considering a motivated expansion to a longer paper.
“Hidden Gems" from The Literature of Parkinsonism
The goal of articles in this section is to provide the current generation of readers with significant clinical observations that were published years ago and might be neglected in current reviews or textbooks. Articles should provide an overview of up to 1,000 words, and can add up-to-date insights. Including a short abstract and keywords is recommended as it will help your article's discoverability. They can focus on a single paper, or cite more than one “hidden gem” dealing with the same disorder. This section is by invitation only. If you wish to write for this section, then please first discuss your idea with the Associate Editor for "Hidden Gems": Peter LeWitt.
Opinion/Position Papers
Opinion or Position Papers provide readers with a snapshot update of a highly topical subject in which the author shares their perspective and thoughts on advances and critical issues in the field and speculates on potential outcomes and future developments. These articles are not intended to provide a comprehensive review of a subject area, rather the intention is to help foster debate and discussion around key areas of Parkinson’s disease research and therapy. Position Papers present an arguable opinion about an issue and can be supported by reasonable preponderance of empirical evidence. Guidelines:
Hypotheses
A hypothesis article should be a balanced and insightful consideration of a topic with novel hypotheses well presented and supported. The article should be prepared as a Research Report but without Methods or Results sections.
Book Reviews
Book reviews should be 750 words or less and without sections. Suggestions can be proposed to the Editors-in-Chief.
Letters to the Editor
These are short letters to JPD that are either: A) Relating to a specific issue/case history. Authors can submit a Letter to the Editor of 1000 words or less for possible inclusion. The Letter should include an abstract (100 words max) and a Plain Language Summary, but no other subdivisions, and should not include more than 15 references and one figure or table. B) Comments of 1000 words or less concerning prior articles published in JPD or elsewhere. These letters should have a title, include appropriate references, and include the corresponding author's e-mail address. Letters can be edited, sometimes extensively, to sharpen their focus. They will be accepted, or may be sent for peer review, at the discretion of the Editors. The author of the original paper will be offered to write a response.
Commentaries
Commentaries can be around 1000 words with an abstract, including a Plain Language Summary, and no other subdivisions. It should not include more than 15 references and one figure or table.
The journal endorses the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first participant enrollment. However, consistent with the AllTrials campaign, retrospectively registered trials will be considered if the justification for late registration is acceptable. The trial registry name and URL, and registration number must be included at the end of the abstract.
If your research involves animals, you will be asked to confirm that you have carefully read and adhered to the ARRIVE guidelines.
The preferred format for your manuscript is Word. You do not need to follow a template, but please ensure your heading levels are clear, and the sections clearly defined.
Your article title, keywords, and abstract all contribute to its position in search engine results, directly affecting the number of people who see your work. For details of what you can do to influence this, visit How to help readers find your article online.
Your manuscript’s title should be concise, descriptive, unambiguous, accurate, and reflect the precise contents of the manuscript. A descriptive title that includes the topic of the manuscript makes an article more findable in the major indexing services.
• The full list of authors including names and affiliations of each
• The listed affiliation should be the institution where the research was conducted. If an author has moved to a new institution since completing the research, the new affiliation can be included in a note at the end of the manuscript – please indicate this on the title page.
• All persons eligible for authorship must be included at the time of submission (please see the authorship section for more information).
• Contact information for the corresponding author: name, institutional address, phone, email
Please include a structured abstract of 250 words between the title and main body of your manuscript that concisely states the purpose of the research, major findings, and conclusions. If your research includes clinical trials, the trial registry name and URL, and registration number must be included at the end of the abstract. Submissions that do not meet this requirement will not be considered.
For clinical trials, the trial registry name and URL, and registration number must be included at the end of the abstract.
This journal includes video abstracts. For more information on how to prepare a plain language summary, please see this page.
A plain language summary (PLS) must be provided for all article types that require an abstract. The plain language title (approx. 50 words) and plain language summary (approx. 300 words) should describe the article using non-technical language, making it accessible to a wider network of readers. More information and guidance on how to write a PLS can be found on our Author Gateway.
PLS are published directly below the scientific abstract and are open access making it available online for anyone to read. Peer review of the PLS will be conducted following our PLS reviewer guidelines. When submitting, authors should enter their plain language title and plain language summary into the box provided in the submission system. The PLS does not need to be provided in the manuscript text or as a separate file. Manuscripts without a PLS, or a PLS which is a direct copy of the scientific abstract, will be returned. If the article type does not require an abstract and therefore does not require a PLS please enter “N/A” in each box.
If you need professional help writing your Plain Language Summary, please visit our Author Services portal.
Please include a minimum of 4 keywords, listed after the abstract. Keywords should be as specific as possible to the research topic.
For guidance on the preparation of illustrations, pictures, and graphs in electronic format, please read Sage’s artwork guidelines.
Figures supplied in color will appear in color online.
Please ensure that you have obtained any necessary permission from copyright holders for reproducing any illustrations, tables, figures, or lengthy quotations previously published elsewhere. For further information including guidance on fair dealing for criticism and review, please see the Frequently Asked Questions page on the Sage Journal Author Gateway.
Example images are found at the bottom of this document.
If you are including an Acknowledgements section, this will be published at the end of your article. The Acknowledgments section should include all contributors who do not meet the criteria for authorship. Per ICMJE recommendations, it is best practice to obtain consent from non-author contributors who you are acknowledging in your manuscript.
Writing assistance and third party submissions: if you have received any writing or editing assistance from a third-party, for example a specialist communications company, this must be clearly stated in the Acknowledgements section and in the covering letter. Please see the Sage Author Gateway for what information to include in your Acknowledgements section. If your submission is being made on your behalf by someone who is not listed as an author, for example the third-party who provided writing/editing assistance, you must state this in the Acknowledgements and also in your covering letter. Please note that the journal editor reserves the right to not consider submissions made by a third party rather than by the author/s themselves.
You will be asked to list the contribution of each author as part of the submission process. Please include the Author Contributions heading within your submission after the Acknowledgements section. The information you give on submission will then show under the Author Contributions heading later at the proofing stage.
Please include a section with the heading ‘Statements and Declarations’ at the end of your submitted article, after the Acknowledgements section [and Author Contributions section if applicable] including each of the sub-headings listed below. If a declaration is not applicable to your submission, you must still include the heading and state ‘Not applicable’ underneath. Please note that you may be asked to justify why a declaration was not applicable to your submission by the Editorial Office.
Please include your ethics approval statements under this heading, even if you have already included ethics approval information in your methods section. If ethical approval was not required, you need to explicitly state this. You can find information on what to say in your ethical statements as well as example statements on our Publication ethics and research integrity policies page.
All papers reporting studies involving human participants, human data or human tissue must state that the relevant Ethics Committee or Institutional Review Board approved the study, or waived the requirement for approval, providing the full name and institution of the review committee in addition to the approval number. If applicable, please also include this information in the Methods section of your manuscript.
Please include any participant consent information under this heading and state whether informed consent to participate was written or verbal. If the requirement for informed consent to participate has been waived by the relevant Ethics Committee or Institutional Review Board (i.e. where it has been deemed that consent would be impossible or impracticable to obtain), please state this. If this is not applicable to your manuscript, please state ‘Not applicable’ in this section. More information and example statements can be found on our Publication ethics and research integrity policies page.
Submissions containing any data from an individual person (including individual details, images or videos) must include a statement confirming that informed consent for publication was provided by the participant(s) or a legally authorized representative. Non-essential identifying details should be omitted. Please do not submit the participant’s actual written informed consent with your article, as this in itself breaches the patient’s confidentiality. The Journal requests that you confirm to us, in writing, that you have obtained written informed consent to publish but the written consent itself should be held by the authors/investigators themselves, for example in a patient’s hospital record. The confirmatory letter may be uploaded with your submission as a separate file in addition to the statement confirming that consent to publish was obtained within the manuscript text. If this is not applicable to your manuscript, please state ‘Not applicable’ in this section.
The journal requires a declaration of conflicting interests from all authors so that a statement can be included in your article. For guidance on conflict of interest statements, see our policy on conflicting interest declarations and the ICMJE recommendations.
If no conflict exists, your statement should read: ‘The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article’.
All articles need to include a funding statement, under a separate heading, even if you did not receive funding. You’ll find guidance and examples on our Funding page.
The Journal is committed to facilitating openness, transparency and reproducibility of research, and has the following research data sharing policy. For more information, including FAQs please visit the Sage Research Data policy pages.
Subject to appropriate ethical and legal considerations, authors are encouraged to:
The journal follows the Sage Vancouver reference style. View the Sage Vancouver guidelines to ensure your manuscript conforms.
Every in-text citation must have a corresponding citation in the reference list and vice versa. Corresponding citations must have identical spelling and year.
Authors should update any references to preprints when a peer reviewed version is made available, to cite the published research. Citations to preprints are otherwise discouraged.
If you use EndNote to manage references, you can download the Sage Vancouver EndNote output file
This Journal can host additional materials online (e.g. datasets, podcasts, videos, images etc.) alongside the full text of the article. Your supplemental material must be one of our accepted file types. For that list and more information please refer to our guidelines on submitting supplemental files.
Authors seeking assistance with English language editing, translation, or figure and manuscript formatting to fit the journal’s specifications should consider using Sage Author Services. Visit Sage Author Services for further information.
As part of the submission process you will need to confirm that this is your original work, that you have the rights in the work, that this is for first publication in this Journal, that it is not being considered for/has not already been published elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you.
Please see our guidelines on prior publication and note that the journal may accept submissions of manuscripts that have been posted on preprint servers.
The journal will consider submissions of manuscripts that have been posted on preprint servers.
Please enter the preprint DOI in the designated field when submitting your manuscript. We advise that you inform the Journal Editorial office about your posted preprint at submission.
Note that you should not post an updated version of your manuscript on a preprint server while it is being peer reviewed.
New submissions should be submitted to: https://mc.manuscriptcentral.com/pkn.
ONLY revised papers should be submitted back to Editorial Manager.
IMPORTANT: Please check whether you already have an account in Sage Track before trying to create a new one. If you have reviewed or authored for the journal in the past year it is likely that you will have had an account created. For further guidance on submitting your manuscript online please visit ScholarOne Online Help.
Manuscripts should only be submitted with the consent of all contributing authors. The individual responsible for submitting the manuscript should carefully check that all those whose work contributed to the manuscript are listed as authors.
Ensure you upload all relevant manuscript files, including any additional supplemental files (including reporting guidelines where relevant).
Please view our authorship policies, which includes information on criteria for authorship, who should be the corresponding author and more.
Please note that AI chatbots, for example ChatGPT, should not be listed as authors. For more information see the policy on Use of ChatGPT and generative AI tools.
The following summary describes the peer review process for this journal:
Identity transparency: Single-anonymized
Reviewer interacts with: Editor
Review information published: None
Your manuscript will undergo an initial evaluation. If it does not conform to the requirements laid out in these guidelines, it will be returned to you for amendments prior to peer review. Manuscripts may be desk rejected without peer review at this point if they are out of scope for the journal or otherwise unsuitable.
After passing the initial evaluation, your manuscript will then be peer reviewed. You can log in at any time to check the status of your manuscript. We will notify you when a decision has been reached.
The journal operates a conventional single-anonymized reviewing policy in which the reviewer’s name is always concealed from the submitting author.
To ensure the integrity of the peer review process we assign reviewers and cannot accept author recommendations.
All manuscripts are reviewed as rapidly as possible, while maintaining rigor. Reviewers make comments to the author and recommendations to the Editor who then makes the final decision on all manuscripts, including those appearing in a special issue or special collection. The Editor or members of the Editorial Board may occasionally submit their own manuscripts for possible publication in the Journal. In these cases, the peer review process will be managed by alternative members of the Board and the submitting Editor/Board member will have no involvement in the decision-making process.
As a COPE member we engage with multiple forms of post-publication discussion in line with wider guidance from Sage: Commentaries, Critiques and Responses.
You can view our complaints and appeals policy here.
Read Sage's complete peer review policy.
The journal and Sage take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. Please read Sage's complete policy on plagiarism and the actions we may take.
After acceptance you will receive instructions via email inviting you to complete the Open Access process. This will include signing the appropriate Creative Commons license and, where applicable, paying the Article Processing Charge (APC) or assigning a bill payer. Once the APC has been processed, your article will be prepared for publication and can appear online within an average of 30 days. Please note that, where an APC is applicable, production work cannot be completed on your manuscript until payment has been received.
Before publication we require the author as the rights holder to sign a Journal Contributor’s Publishing Agreement. The journal publishes manuscripts under Creative Commons licenses. The standard license for the journal is Creative Commons by Attribution Non-Commercial (CC BY-NC), which allows others to re-use the work without permission as long as the work is properly referenced and the use is non-commercial. For more information, you are advised to visit Sage's OA licenses page. Alternative license arrangements are available at the author’s request (e.g. to meet particular funder mandates).
If your manuscript was posted on a preprint server prior to acceptance, you must include a link in your preprint to the final published version of your published article.
Your Sage Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will be made available to the corresponding author via our editing portal, Sage Edit, or by email, and should be returned promptly to avoid delaying publication. Authors are reminded to check their proofs carefully to confirm that all author information, including names, affiliations, sequence, and contact details are correct, and that Funding and Conflict of Interest statements, if any, are accurate. This is the final opportunity to make changes to your manuscript. Further corrections will not be possible after publication. Changes to the author list are not permitted at this stage.
One of the many benefits of publishing your research in an open access journal is the speed to publication. With no page count constraints, your article will be published online in a fully citable form with a DOI number as soon as it has completed the production process. At this time it will be completely free to view and download for all.
OnlineFirst publication: This enables us to publish final articles online immediately, without waiting for assignment to a future issue of the Journal. This usually significantly reduces publication lead time. Visit the Sage Journals help page for more details, including how to cite OnlineFirst articles.
Publication is not the end of the process. Between us, we can ensure that your article is found, read, downloaded and cited as widely as possible. Many of the most effective tactics are those you can do quickly and easily to your network of contacts and peers. Visit the Promote Your Article page on the Sage Journal Author Gateway for numerous resources to help you promote your work.
The Sage Journal Author Gateway has some general advice on how to get published, plus links to further resources. Sage Author Services also offers authors a variety of ways to improve and enhance your article including English language editing, plagiarism detection, and video abstract and infographic preparation.
If you have any questions about publishing with Sage, please visit the Sage Journals Solutions Portal.
You can view our complaints and appeals procedure.
You can direct any questions to the journal’s editorial office:
Bas Bloem, MD, PhD, FRCPE
Editors-in-Chief
Bas.Bloem@radboudumc.nl
Lorraine V. Kalia, MD, PhD, FRCPC
Editors-in-Chief
lorraine.kalia@utoronto.ca